Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q1 2023
Institutional positions in Gain Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +2 vs. Q4 2022
- Shares held
- 1.15M
- +65.7K (+6.1%) vs. Q4 2022
- Total value
- $5.54M
- +$2.15M (+63.5%) vs. Q4 2022
- New holders
- 4
- 5 more added
- Sold out
- 2
- 6 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 50 | $17.4M |
| Q1 2026 | 42 | $15.8M |
| Q4 2025 | 48 | $25.9M |
| Q3 2025 | 38 | $7.70M |
| Q2 2025 | 35 | $6.49M |
| Q1 2025 | 33 | $5.07M |
| Q4 2024 | 25 | $3.94M |
| Q3 2024 | 19 | $2.40M |
| Q2 2024 | 28 | $3.89M |
| Q1 2024 | 26 | $7.04M |
| Q4 2023 | 24 | $5.05M |
| Q3 2023 | 24 | $4.95M |
| Q2 2023 | 24 | $5.68M |
| Q1 2023 | 22 | $5.54M |
| Q4 2022 | 21 | $3.78M |
| Q3 2022 | 23 | $3.95M |
| Q2 2022 | 16 | $3.87M |
| Q1 2022 | 16 | $4.75M |
| Q4 2021 | 19 | $5.71M |
| Q3 2021 | 14 | $6.65M |
| Q2 2021 | 14 | $8.95M |
| Q1 2021 | 12 | $15.0M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Gain Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Greenlight Capital Inc | 546,560 | $2.63M | 0.14% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 94,207 | $454.1K | 0.00% | +4,093+4.5% | Added |
| CM Management, LLC | 90,000 | $434.0K | 0.52% | −20,000−18.2% | Reduced |
| Bridgeway Capital Management, LLC | 60,000 | $289.2K | 0.01% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 58,100 | $280.0K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 52,605 | $253.6K | 0.00% | +52,605 | New |
| Royal Bank of Canada | 39,000 | $188.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 38,700 | $187.0K | 0.00% | +5,500+16.6% | Added |
| BlackRock Inc. | 24,778 | $119.4K | 0.00% | −202−0.8% | Reduced |
| Raymond James & Associates | 20,000 | $96.4K | 0.00% | −4,000−16.7% | Reduced |
| Dimensional Fund Advisors LP | 18,607 | $89.7K | 0.00% | +6,661+55.8% | Added |
| Citadel Advisors LLC | 17,447 | $84.1K | 0.00% | +17,447 | New |
| Susquehanna International Group, LLP | 15,172 | $73.1K | 0.00% | +15,172 | New |
| Northern Trust Corp | 13,277 | $64.0K | 0.00% | +731+5.8% | Added |
| Wealth Alliance Advisory Group, LLC | 12,502 | $60.3K | 0.02% | −6,249−33.3% | Reduced |
| Cannell Capital LLC | 12,371 | $59.6K | 0.01% | 00.0% | Unchanged |
| GWM Advisors LLC | 10,500 | $54.1K | 0.00% | +10,500 | New |
| Advisor Group Holdings, Inc. | 10,000 | $48.2K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,844 | $33.0K | 0.00% | −308−4.3% | Reduced |
| UBS Group AG | 4,305 | $20.8K | 0.00% | −2,984−40.9% | Reduced |
| Wells Fargo & Company | 3,713 | $17.9K | 0.00% | +10.0% | Added |
| Morgan Stanley | 800 | $3.86K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,742−100.0% | Sold out |
| Hoey Investments, Inc | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Telemetry Investments, L.L.C. | – | – | – | – | Not filed |